Goldman Sachs initiated coverage of Krystal Biotech with a Buy rating and $160 price target. Krystal is a commercial stage biotechnology company currently launching Vyjuvek as the first approved therapy for dystrophic epidermolysis bullosa, the analyst tells investors in a research note. The firm is positive on Vyjuvek’s near- and long-term potential and sees a blockbuster opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KRYS:
- Biotech Alert: Searches spiking for these stocks today
- Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
- Krystal Biotech reports Q3 EPS $2.79 vs ($1.17) last year
- KRYS Upcoming Earnings Report: What to Expect?
- Krystal Biotech initiated with an Overweight at Cantor Fitzgerald
